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A B S T R A C T
Background
People affected with sickle cell disease are at high risk of infection from Haemophilus influenzae type b. Before the implementation of
Haemophilus influenzae type b conjugate vaccination in high-income countries, this was responsible for a high mortality rate in children
under five years of age. In African countries, where coverage of this vaccination is still extremely low, Haemophilus influenzae type b
remains one of the most common cause of bacteraemias in children with sickle cell disease. The increased uptake of this conjugate
vaccination may substantially improve the survival of children with sickle cell disease.
Objectives
The primary objective was to determine whetherHaemophilus influenzae type b conjugate vaccines reduce mortality and morbidity in
children and adults with sickle cell disease.
The secondary objectives were to assess the following in children and adults with sickle cell disease: the immunogenicity ofHaemophilus
influenzae type b conjugate vaccines; the safety of these vaccines; and any variation in effect according to type of vaccine, mode of
administration (separately or in combination with other vaccines), number of doses, and age at first dose.
Search methods
We searched theCochraneCystic Fibrosis andGeneticDisordersGroup’sHaemoglobinopathiesTrialsRegister, compiled fromelectronic
database searches and handsearching of journals and conference abstract books. We also contacted relevant pharmaceutical companies
to identify unpublished trials.
Date of last search: 23 November 2015.
Selection criteria
All randomised and quasi-randomised controlled trials comparing Haemophilus influenzae type b conjugate vaccines with placebo or
no treatment, or comparing different types of Haemophilus influenzae type b conjugate vaccines in people with sickle cell disease.
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Data collection and analysis
No trials of Haemophilus influenzae type b conjugate vaccines in people with sickle cell disease were found.
Main results
There is an absence of evidence from randomised controlled trials relating to the subject of this review.
Authors’ conclusions
There has been a dramatic decrease in the incidence of invasiveHaemophilus influenzae type b infections observed in the post-vaccination
era in people with sickle cell disease living in high-income countries. Therefore, despite the absence of evidence from randomised
controlled trials, it is expected that Haemophilus influenzae type b conjugate vaccines may be useful in children affected with sickle cell
disease, especially in African countries where there is a high prevalence of the disease. The implementation of childhood immunisation
schedules, including universal Haemophilus influenzae type b conjugate vaccination, may substantially improve the survival of children
with sickle cell disease living in low-income countries. We currently lack data to evaluate the potential effect of Haemophilus influenzae
type b vaccination among unvaccinated adults with sickle cell disease. Further research should assess the optimal Hib immunisation
schedule in children and adults with sickle cell disease.
P L A I N L A N G U A G E S U M M A R Y
Vaccines for preventing severe Haemophilus influenzae type b (Hib) infections in people with sickle cell disease
Review question
We reviewed the available evidence from randomised controlled trials about how effective and safeHaemophilus influenzae type b (Hib)
conjugate vaccines are for people with sickle cell disease.
Background
People with sickle cell disease are at high risk of infection from Hib, which was responsible for a high death rate in children under five
years of age before Hib conjugate vaccination was introduced in high-income countries. In African countries, where coverage for this
vaccination is extremely low, Hib remains one of the most common causes of bacteraemias (bacteria in the blood) in children with
sickle cell disease. Another Cochrane review on conjugate vaccines for preventing Hib infections in children under five years of age has
shown that Hib conjugate vaccines were safe and effective but it did not specifically look at children with sickle cell disease, who have
a high risk of this infection.
Search date
The evidence is current to: 23 November 2015.
Study characteristics
We did not find any randomised controlled trials comparing Hib conjugate vaccines with placebo (’dummy’ treatment) or no treatment
in people with sickle cell disease.
Key results and quality of the evidence
There are no randomised controlled trials of this vaccine in people with sickle cell disease. However, there has been a dramatic decrease
in the occurrence of severe Hib infections in children with sickle cell disease living in high-income countries since the vaccination
has been included in childhood immunisation schedules. Therefore, including universal Hib conjugate vaccination in low-income
countries may improve the survival of children with sickle cell disease. There is not enough data to allow us to assess the potential effect
of Hib vaccination in unvaccinated adults with sickle cell disease. Future trials should assess the ideal Hib immunisation schedule in
children and adults with sickle cell disease.
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B A C K G R O U N D
Description of the condition
Sickle cell disease (SCD) is a group of genetic haemoglobin disor-
ders, caused by the inheritance of a sickle ß globin gene (HbS) from
one parent and of another altered ß globin gene (HbS, HbC, ß-
thalassaemia) from the second parent. This includes the homozy-
gous state (SS) as well as compound heterozygous states such as
SC, S/ß0thal, S/ß+thal and SD. Sickle cell trait is defined by in-
heritance of a single sickle ß globin gene and confers some type of
protection against falciparum malaria. Therefore, SCD is partic-
ularly frequent among people originating from the highly malari-
ous regions, especially Sub-Saharan Africa (where 85% of all SCD
occurs) (Modell 2008), India, the Middle East and the Mediter-
ranean region. Due to human migration, the sickle ß globin gene
has been spread widely throughout the world (Davies 1997) with
over 300,000homozygous (SS) neonates born per year (Piel 2013),
making SCD a global public health issue recognised by the United
Nations (UN) and the World Health Organization (WHO). The
disease is responsible for chronic haemolysis, resistance to nitric
oxide (NO) bioactivity, small vessel obstruction, ischaemia-reper-
fusion injury and increased susceptibility to infections (Overturf
1999).
In low-income countries, SCD is associated with a very high early-
life mortality rate, especially in Africa (Rahimy 2003), where it
contributes to 5% of deaths in children under five years of age
(WHO 2006a). Invasive bacterial infections are responsible for a
substantial percentage of the high mortality rate and it was esti-
mated that half of the patients in Sub-Saharan Africa die of infec-
tion before the age of five years (Fleming 1989). In high-income
countries, such as the USA, before the implementation of early
screening and prevention programs (prophylactic penicillin, im-
munization), bacterial infections were also a major cause of mor-
tality and morbidity in SCD, particularly in early childhood (Gill
1995).
Children affected with SCD are at high risk of infection from
encapsulated bacteria, especially Streptococcus pneumoniae and
Haemophilus influenzae type b (Hib) (Powars 1983; Ward 1976),
the incidence of invasive pneumococcal infection being the highest
(Zarkowsky 1986). The main reason for this predisposition is that
they may develop asplenia or hyposplenia as early as three months
of age with a loss of splenic function beginning before 12 months
of age in more than 80% of infants (Rogers 2011). By two years of
age, half of the children affected with SCD have functional asple-
nia (Pearson 1985). The other known immunopathologic mech-
anisms contributing to an increased vulnerability to encapsulated
bacteria in children affectedwith SCD are defects in the adaptative
immune system with dysfunctional immunoglobulin G (IgG) and
immunoglobulin M (IgM) antibody responses, defects in alterna-
tive pathway fixation of complement and defective opsonisation
(Booth 2010; Overturf 1999).
Studies performed before systematic implementation of Hib con-
jugate vaccination showed that 90% of all invasive Haemophilus
influenzae infections in children were due to Hib (Anderson 1995;
Asensi 1995). This bacteria is an important cause of meningi-
tis, septicaemia, pneumonia, and other invasive diseases, such as
epiglottitis, cellulitis, arthritis, osteomyelitis, and pericarditis. In
the pre-vaccination era, it has been estimated to have caused two
to three millions cases of serious diseases and more than half a
million deaths annually worldwide (Peltola 2000).
Historically, Hib was responsible for a high mortality rate in chil-
drenwith SCDunder five years of age (Zarkowsky 1986) and in the
early 1980s, in the USA, a four-fold increased risk ofHaemophilus
in uenzae septicaemia in children with SCD under nine years of
age was observed (Powars 1983). In a study following 694 chil-
dren enrolled at less than six months of age between 1978 and
1988 in the USA, the mortality was of two out of 10 cases of
Hib bacteraemia (Gill 1995). Since the introduction of Hib con-
jugate vaccination, a dramatic decrease in the incidence of inva-
sive Hib infections has been observed in the USA with no cases
of Haemophilus in uenzae bacteraemia in a retrospective study
reviewing the medical records of 815 children with SCD followed
at the Children’s Hospital of Philadelphia from 2000 to 2010
(Ellison 2013). However, this evolution has not been observed on
the African continent, where Hib remains one of the most com-
mon organisms involved in bacteraemias in children affected with
SCD, accounting for 12% to 19% of cases (Kizito 2007; Williams
2009). This may be due to an extremely low coverage for Hib
vaccination, which remains below 10% in children with SCD in
many different African countries (Nacoulma 2006).
Description of the intervention
Since the 1970s, Hib vaccinations have been used to protect chil-
dren and adults affected with SCD (Pearson 1977); Hib polysac-
charide vaccines, consisting of the type b capsular polysaccharide,
polyribosylribitol phosphate (PRP), were first available but had a
weak immunogenicity when administered under two years of age
(Rubin 1989). This was probably because bacterial polysaccha-
rides do not generate memory responses in B cells. Yet, those with
SCD younger than two years of age have the highest risk of fulmi-
nant infections related to encapsulated bacteria. Since the 1990s,
Hib conjugate vaccines have been available; these were created by
covalently attaching the PRP to a protein carrier, resulting in a
T-cell-dependant immune response with the production of high-
affinity antibodies and the formation of memory B cells. There-
fore, Hib conjugate vaccines have a much better immunogenicity
than Hib polysaccharide vaccines (Frank 1988) and are consid-
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ered as safe and highly immunogenic in children with SCD (de
Montalembert 1993;Goldblatt 1996; Kaplan 1992; Rubin 1992).
Hib conjugate vaccines are routinely administered to all infants
living in high-income countries, including those with SCD, with
catch-up vaccination until five years of age; and the WHO rec-
ommends that they should be included in all routine infant im-
munization programs all over the world. However, immunization
against Hib has reached only a fraction of the children living in
low-income countries (WHO 2006b) and therefore, the burden
of Hib disease is much more significant in those countries, espe-
cially in Africa (Watt 2009). Four different Hib conjugate vac-
cines have been licensed, differing by the type of protein carrier
(tetanus toxoid for PRP-T which is the most widely used, non-
toxic mutant diphtheria toxin for HbOC, outer membrane pro-
tein ofNeisseria meningitidis for PRP-OMP and diphtheria toxoid
for PRP-D which is no longer used in young infants because of
its poor immunogenicity). They can be administered separately
or in combination with other vaccines. Different immunization
schedules exist. The schedule recommended by the WHO con-
sists in a three-dose primary series, including a first dose which
may be given to infants as young as six weeks of age, and a second
and third doses at four-to-eight-week intervals along with dipthe-
ria-tetanus-pertussis (DTP). If given, the booster dose should be
administered between 12 months and 18 months of age (WHO
2006b). In the USA, the schedule recommended by the Advisory
Commitee on Immunization Practices (Briere 2014) includes a
primary series at two, four and six months of age (the dose at age
six months being not indicated if PRP-OMP is used at two and
four months of age), a booster dose at age 12months to 15months
and an additional dose for unvaccinated or partially vaccinated
persons aged five years or older who have a high-risk condition,
including SCD.
How the intervention might work
A Cochrane review has shown that Hib conjugate vaccines were
safe and effective in preventing Hib diseases in children under five
years of age (Swingler 2009).
Immunization with Hib conjugate vaccines is considered to have
largely controlled infections caused by this pathogen in SCD
children living in high-income countries (Ellison 2013; Overturf
1999).
Why it is important to do this review
The Cochrane review on conjugate vaccines for preventing Hib
infections in children aged less than five years did not undertake
a specific analysis of a subgroup of children with SCD (Swingler
2009). Considering that the risk of severe Hib infections is ex-
tremely high in children with SCD, and by analogy with pneu-
mococcal conjugate vaccines, whose immunogenicity has been
demonstrated in people with SCD (Davies 2004), it justifies a
specific review of this highly-exposed population.
In unvaccinated, or partially vaccinated, children aged five years
or older who have high risk conditions, including SCD, it is rec-
ommended to administer one dose of Hib vaccine (Briere 2014).
However, there is no published systematic review on Hib vaccines
in children older than five years or in adults and therefore, in some
clinical guidelines, administration of a single dose of Hib vaccine
in unvaccinated adults with SCD is recommended (Briere 2014;
SickleCell Society 2008), while it is notmentioned in others (NIH
2002).
This review is motivated by the fact that there is no published
systematic review on Hib vaccines in children or adults with SCD
and yet the benefit could be very different in this population,
notably because of the high risk reduction. Such a review could
help produce evidence-based recommendations and argue that the
implementation of the recommended universal childhood immu-
nisation program, including Hib conjugate vaccination, should
be a public health priority in low-income countries, especially in
African countries, where it could substantially affect the survival
of children with SCD.
O B J E C T I V E S
Primary objective
To determine whether Hib conjugate vaccines reduce Hib mor-
tality and morbidity in children (aged under 18 years) and adults
(aged 18 years and over) with SCD.
Secondary objectives
1. To assess the immunogenicity of Hib conjugate vaccines in
children and adults with SCD.
2. To assess the safety of Hib conjugate vaccines in children
and adults with SCD.
3. To determine any variation in effect according to type of
vaccine, mode of administration (separately or in combination
with other vaccines), number of doses, and age at first dose.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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All randomised controlled trials (RCTs) and quasi-RCTs.
Types of participants
People of all ages and both sexes affected with SCD of all types
including SS, SC, S/ß0thal, S/ß+thal and other combinations such
as Hb SD or Hb SO (confirmed by high performance liquid chro-
matography,Hbelectrophoresis and sickle solubility testwith fam-
ily studies or DNA tests), regardless of the setting.
Types of interventions
Comparisons of all the available Hib conjugate vaccines with
placebo or no treatment.
Comparison between different types of Hib conjugate vaccines.
Types of outcome measures
Primary outcomes
1. Mortality from Hib infections
2. Overall mortality
3. Acute morbidity from Hib infections (e.g. vaso-occlusive,
hyperhaemolytic and sequestration crises, septicaemia,
meningitis, pneumonia, acute chest syndrome, epiglottitis,
cellulitis, arthritis, osteomyelitis, pericarditis).
Secondary outcomes
1. Immunogenicity of Hib conjugate vaccines (e.g. antibody
levels and serum opsonic activity in order to assess the biologic
function of the antibody)
2. Adverse events related to the vaccines (e.g. redness, swelling,
fever, pain, vaso-occlusive crisis, irritability, drowsiness, loss of
appetite, vomiting)
3. Standard quality of life measures
i) limitation of physical activity
ii) limitation in role activity
iii) frequency of bodily pains
iv) perception of general health
v) frequency of absence from school
vi) lost time at work
vii) frequency of hospitalisation
viii) any other relevant measures reported
Search methods for identification of studies
Electronic searches
The review authors searched for relevant trials from the
Cochrane Cystic Fibrosis and Genetic Disorders Group’s
Haemoglobinopathies Trials Register using the terms: sickle cell
AND *influenza*.
The Haemoglobinopathies Trials Register is compiled from elec-
tronic searches of theCochraneCentral Register of ControlledTri-
als (CENTRAL) (updated each new issue ofTheCochrane Library)
and weekly searches of MEDLINE. Unpublished work is iden-
tified by searching the abstract books of five major conferences:
the EuropeanHaematology Association conference; the American
Society of Hematology conference; the British Society for Haema-
tology Annual Scientific Meeting; the Caribbean Health Research
Council Meetings; and the National Sickle Cell Disease Program
Annual Meeting. For full details of all searching activities for the
register, please see the relevant section of the Cochrane Cystic
Fibrosis and Genetic Disorders Group Module.
Date of the most recent search of the Group’s
Haemoglobinopathies Trials Register: 23 November 2015.
Searching other resources
The review authors planned to review the bibliographic references
of all retrieved articles and to contact authors in an attempt to
identify additional reports of trials. They also attempted to identify
unpublished trials by contacting pharmaceutical companies.
Data collection and analysis
Selection of studies
Two review authors, Mariane de Montalembert (MdM) and Sli-
mane Allali (SA), independently assessed trials for inclusion in the
review. This was done by firstly examining titles and abstracts of
records retrieved from the search and excluding irrelevant reports;
and secondly, by examining each full-text of the remaining poten-
tially relevant reports to determine eligibility. There was no dis-
agreement on the suitability of a trial for inclusion.
Data extraction and management
Two review authors (MdM and SA) planned to independently
extract the data from the included trials using a data extraction
form (collecting information on trial methods, participants, in-
tervention, control and outcomes). The review authors planned
to resolve any disagreements by discussion with a third author,
Martin Chalumeau (MC). If possible, they planned to extract data
for primary outcomes and quality of life measures at one, three,
six, 12 months and annually thereafter. They planned to extract
immunogenicity measures four weeks after vaccination, as well as
adverse events occurring up to 72 hours after vaccination. If any
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outcome data had been recorded at other time points, then the
review authors would have considered examining these as well.
Assessment of risk of bias in included studies
Two review authors (MdM and SA) planned to independently as-
sess the risk of bias of each trial by evaluating selection bias (se-
quence generation and allocation concealment), performance bias
(blinding of participants and personnel), detection bias (blind-
ing of outcome assessment), attrition bias (unavailable outcome
data) and reporting bias, according to the recommendations of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). They planned to use Cochrane’s tool for assessing the risk
of bias and to resolve any disagreements between authors by dis-
cussion with a third author (MC).
Measures of treatment effect
For dichotomous outcome data (e.g. mortality from Hib infec-
tions, overall mortality, acute morbidity fromHib infections, lim-
itation in physical activity) the review authors planned to calculate
the risk ratio (RR), the number needed to treat (NNT) and their
95% confidence intervals (95% CI).
For continuous outcome data (e.g. antibody levels, frequency of
bodily pain) they planned to calculate a mean difference (MD) or
if different scales were used to evaluate the same outcome, a stan-
dardised mean difference (SMD), both with their corresponding
95% CI.
Unit of analysis issues
For the primary outcomes measured longitudinally at different
time points, the review authors planned to perform a separate
analysis at each time point in order to avoid a unit-of-analysis
error.
If cluster-randomised trials had been available, the review authors
would have conducted the analysis at the same level as the alloca-
tion, using a summary measurement from each cluster.
Dealing with missing data
If important data had been missing from the included trials, the
review authors would have tried to obtain these through contact
with trial investigators. If these data had remained unavailable,
they would have considered the potential effects of missing data
on the results of the review. If the review authors had assumed data
were missing at random, they would have ignored these and they
would have based their analyses on the available data.
Assessment of heterogeneity
The review authors planned to test for heterogeneity between trials
by using the Chi2 test (significance set at P < 0.10). In addition
to this, they planned to assess the quantity of inconsistency across
trials in a meta-analysis by using the I2 statistic (I2 values greater
than 50% indicating substantial statistical heterogeneity). They
also planned to assess heterogeneity through a visual examination
of the combined data presented in the forest plots.
Assessment of reporting biases
If the review authors had included more than 10 trials in the
review, they would have tried to identify reporting biases by using
a funnel plot (Egger 1997). If asymmetry had been present, they
would have explored possible causes including publication bias,
high risk of bias, and true heterogeneity.
Data synthesis
The review authors planned to carry out statistical analysis to com-
pare Hib conjugate vaccines with placebo or no treatment using
the Cochrane Review Manager software (RevMan 2014).
If they had found no substantial heterogeneity (as defined above)
between the trials, they would have performedmeta-analyses using
a fixed-effect model. Otherwise they would have used a random-
effects model.
Subgroup analysis and investigation of heterogeneity
If the review authors had been able to include sufficient data,
they would have investigated statistically significant heterogeneity
identified by performing subgroup analyses according to:
• age at first vaccination (under five years of age versus five
years and over);
• type of vaccine;
• number of doses;
• setting (high-income versus low-income countries).
Sensitivity analysis
If the review authors had included an appropriate number of trials
in the review, they would have performed sensitivity analyses in
order to assess the robustness of the review’s results by repeating
the analysis after exclusion of the trials which:
1. utilised quasi-randomisation methods;
2. were assessed as having an overall high risk of bias.
R E S U L T S
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Description of studies
Results of the search
Three individual primary trials were identified by the electronic
searches (Ambrosino 1986; Frank 1988; Souza 2010); no further
trials were identified by contacting authors and pharmaceutical
companies.
Included studies
No trials were included in the review.
Excluded studies
One trial was excluded because it did not deal with Hib but with
influenza vaccines (Souza 2010); one trial was excluded because it
dealt with passive immunization against Hib (Ambrosino 1986);
and one was considered more closely for inclusion, but it was ex-
cluded since it compared immunogenicity between a Hib con-
jugate vaccine (PRP-D) and a Hib polysaccharide vaccine (PRP)
(Frank 1988). Therefore, no trials were included in the review.
Risk of bias in included studies
No trials were included in the review.
Effects of interventions
No trials were included in the review.
D I S C U S S I O N
Summary of main results
No randomised controlled trials (RCTs) comparing Hib conjugate
vaccines with placebo or no treatment in people with sickle cell
disease (SCD) were identified in our systematic review. Thus, it is
not possible to answer our reviewquestionusing results issued from
trials with the highest level of evidence, although other sources of
evidence may be helpful.
Overall completeness and applicability of
evidence
No trials were included in the review.
Quality of the evidence
No trials were included in the review.
Potential biases in the review process
There may be some publication bias in the review process given
trials with negative results are less likely to be published; but no
additional unpublished trials were identified by contacting authors
and pharmaceutical companies.
Agreements and disagreements with other
studies or reviews
The Cochrane review on conjugate vaccines for preventing Hib
infections in children aged less than five years has shown that Hib
conjugate vaccines were safe and effective in preventing Hib dis-
eases (Swingler 2009). In this review, the effect size was major
with a relative risk for invasive Hib disease of 0.20 (95% confi-
dence interval 0.07 to 0.54). How could the results of this review
be related to people with SCD in particular? First, the baseline
risk is probably different and much higher among people with
SCD than in the general population. It has been reported in the
early 1980s in the USA that there was a four-fold increased risk of
Haemophilus influenzae septicaemia in children with SCD under
nine years of age (Powars 1983); but we do not know the relative
burden of invasive Hib disease in people with SCD living in low-
income countries. However, it has been shown in a recent review,
including 33 studies from Africa with data on SCD and bacte-
rial disease, that those with invasive Hib disease had a 13- to 17-
times greater odds of having SCD than controls (Ramakrishnan
2010). Thus, if a complete vaccination offers the same protection
against Hib among people with SCD, the effect size would be
much higher. Secondly, SCDmodifies host response to pathogens
and concerns may rise on host response to vaccines and conse-
quently on their efficacy. However, vaccine-induced protection is
usually evaluated by the immunogenicity and although dysfunc-
tional IgG and IgM antibody response has been reported in people
with SCD (Overturf 1999), Hib conjugate vaccines seem to be
highly immunogenic in this population (de Montalembert 1993;
Goldblatt 1996; Kaplan 1992; Rubin 1992) with IgG titers com-
parable to those obtained in healthy children. By analogy, the im-
munogenicity of pneumococcal conjugate vaccines has also been
demonstrated in people with SCD (Davies 2004). The dramatic
decrease in the incidence of severe Hib infections in people with
SCD living in high-income countries in the post-vaccination era
cannot be explained only by herd immunity since Hib strains are
still circulating and are responsible for meningitis in individuals
with an incomplete vaccination schedule and in those affectedwith
immunological deficiency, but not in those with SCD (Pop-Jora
2008). The condition is not considered a risk factor for Hib con-
jugate vaccine failure in childhood (Heath 2000). Thirdly, the sa-
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fety of Hib conjugate vaccines in people with SCD may be ques-
tioned. No serious adverse effects, but some essentially mild local
reactions, fever, irritability and crying were reported in the tri-
als (a total of 257,000 infants) included in the above-mentioned
Cochrane review (Swingler 2009), but the adverse effects related
to vaccines might be more severe in people with SCD. However,
Hib conjugate vaccines are considered to be safe in people with
SCD (de Montalembert 1993; Rubin 1992) and only mild local
reactions, pain and fever have been reported. To date, no impor-
tant adverse effects have been reported in people with SCD by the
Vaccine Safety Datalink, which started in 1990 and the pharma-
covigilance data in high-income countries are reassuring. In a ran-
domised controlled trial, in an unselected population of 42,848
infants at two, three and four months of age, in Gambia (where
SCD prevalence is 1% (Grosse 2011)), a Hib PRP-T conjugate
vaccine mixed with diptheria-tetanus-pertussis (DTP) was com-
pared to DTP alone. In this trial, no serious adverse effects were
reported across the whole population, and it is thus probable that
around 200 children with SCD received Hib conjugate vaccine
without any serious adverse effect (Mulholland 1997).
Thus, given a highest baseline risk, a good serological responsive-
ness, observational data from high income countries and lack of
concerns on safety, Hib conjugate vaccines in people with SCD
are probably at least as effective and as safe as in the general pop-
ulation.
In unvaccinated adults affected with SCD, we ignore the base-
line risk for Hib infections and consequently there is no consen-
sus on Hib conjugate vaccination in this population. In the gen-
eral population, Hib vaccination is not recommended for unvac-
cinated adults and children aged more than five years because, in
the pre-vaccination era, invasive Hib disease affected almost ex-
clusively children aged less than five years (Peltola 2000). Healthy,
unvaccinated adults have protective immunity against Hib due to
natural anti-Hib antibodies that may have been induced by ex-
posure to some common environmental bacteria that carry anti-
gens cross-reacting with PRP (Nix 2012). However, in high-in-
come countries, in the post-vaccination era, Hib cases no longer
occur in vaccinated children but a few cases now occur in adults
with low Hib antibody levels and co-morbidities, including asple-
nia (Collins 2013). Hib conjugate vaccines seem to have a high
immunogenicity in asplenic adults (Meerveld-Eggink 2011) and
are considered as safe and effective in splenectomized and non-
splenectomized adults with thalassemia (Cimaz 2001) and in the
elderly (Lottenbach 2004). These findings suggest that unvacci-
nated adults with SCD might benefit from Hib conjugate vacci-
nation to achieve protective immunity but we lack data to evaluate
the potential effect of Hib vaccination in this population in high
or low-income countries.
The correct implementation of universal Hib conjugate vaccina-
tion into routine childhood immunisation schedules has largely
controlled Hib infections in SCD children living in high-income
countries and itmay improve the survival of childrenwith SCD liv-
ing in low-income countries, especially in African countries where
vaccination reaches only a fraction of them (Nacoulma 2006) and
where Hib remains one of the most common organisms, responsi-
ble for invasive infections in SCD children (Kizito 2007;Williams
2009).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
No RCTs comparing Hib conjugate vaccines with placebo or no
treatment in people with SCD were found for inclusion in this re-
view. However, since safety and efficacy of Hib conjugate vaccines
have been shown by the Cochrane review on conjugate vaccines
for preventing Hib infections in children aged less than five years,
and given a highest baseline risk of Hib infections in people with
SCD, a high immunogenicity of Hib conjugate vaccines, dramatic
observational data from high-income countries in the post-vacci-
nation era and lack of concerns on safety, it is reasonable to expect
that Hib conjugate vaccines could particularly benefit children af-
fected with SCD. The implementation of childhood immunisa-
tion schedules including universal Hib conjugate vaccination may
improve the survival of children with SCD and should be a public
health priority in low-income countries. We lack data to evaluate
the potential effect of Hib vaccination among unvaccinated adults
with SCD.
Implications for research
The proven efficacy and safety of Hib conjugate vaccines in non-
SCD individuals, the reassuring immunogenicity and safety data
in those affected with SCD and the fact that invasive Hib infec-
tions have become extremely rare in people with SCD living in
high-income countries following the introduction of Hib conju-
gate vaccination into routine childhood immunisation schedules,
are sufficient to preclude controlled trials comparing Hib conju-
gate vaccines with placebo in people with SCD. Further inves-
tigations (especially comparing immunogenicity of different Hib
vaccination schedules in the short, medium and long term) are
required to assess the optimal Hib immunisation schedule in chil-
dren and adults with SCD.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ambrosino 1986 Deals with passive immunization against Hib.
Frank 1988 Comparison of a Hib conjugate vaccine (PRP-D) and a Hib polysaccharide vaccine (PRP)
Souza 2010 Does not deal with Hib but with influenza vaccines.
Hib: Haemophilus influenzae type b
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Glossary
Term Definition
Cellulitis spreading bacterial infection underneath the skin surface
Chronic haemolysis chronic destruction of red blood cells
Conjugate vaccine vaccine containing bacterial capsular polysaccharide joined to a protein to enhance
immunogenicity
Encapsulated bacteria bacteria that have an outer covering made of polysaccharide
Epiglottitis inflammation of the epiglottis
Fulminant infections infections coming on suddenly with great severity
Functional asplenia absence of splenic function due to spontaneous infarction of the spleen
Haemophilus influenzae Gram-negative, coccobacillary, facultatively anaerobic bacterium that was first de-
scribed in 1892 by Richard Pfeiffer during an influenza pandemic
Hyposplenia reduced splenic functioning
IgG immunoglobulin G
IgM immunoglobulin M
Immunogenicity capacity of producing an immune response
Ischaemia-reperfusion injury tissue damage caused by oxidative stress when blood supply returns to the tissue
after a period of ischaemia
Nitric oxide (NO) soluble gas, continuously synthesized in endothelial cells, whose vasodilator activity
is decreased in SCD
Opsonisation immune process by which a pathogen is targeted for destruction by a phagocyte
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(Continued)
Osteomyelitis infection of the bone
Pericarditis inflammation of the pericardium
Quasi-randomised controlled trial (quasi-RCT) trial using a quasi-random method of allocation (such as alternation, date of birth,
or hospital number)
Septicaemia invasion of the bloodstream by bacteria, accompanied by a systemic inflammatory
response
Sequela pathological chronic condition resulting from a disease as a complication of an
acute morbidity
Serum opsonic activity ability of antibodies in blood serum to attach to bacteria to make them more
susceptible to destruction by phagocytes
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